Toyota ShareLunker Program 2026 Season Delivers 18 Legacy Class Fish From 10 Texas Lakes

The Texas Parks and Wildlife Department announced results of the 2026 Toyota ShareLunker collection season, celebrating the program's 40th anniversary with 18 Legacy Class ShareLunkers submitted from 10 different public lakes across Texas. Two waterbodies (Hords Creek Reservoir and Ellison Creek Reservoir) recorded their first Legacy Class fish, while four lakes set new waterbody records. O.H. Ivie retained bragging rights for most entries for the sixth consecutive season with five Legacy Class ShareLunkers, bringing its total to 63 since 2020. The program focuses on habitat improvement, stocking programs, and genetic research for largemouth bass conservation.

Governor Spanberger Signs Momnibus Bills to Improve Maternal Healthcare, Support Virginia Mothers

Governor Abigail Spanberger signed the Virginia Momnibus legislative package on April 22, 2026, enacting four bipartisan bills to improve maternal healthcare coverage. The package includes HB1400 expanding maternal mental healthcare screenings, HB1403 directing the Department of Health to develop a Severe Maternal Morbidity reporting system, HB425 authorizing Medicaid reimbursements for remote monitoring of high-risk pregnant women, and HB1353 directing the Commissioner of Health to assess a statewide maternal health safety initiative. The legislation targets Virginia's high maternal mortality rate, particularly for Black women who face elevated risks compared to other demographics.

Governor Spanberger Statement on Redistricting Referendum Outcome

Governor Abigail Spanberger released a statement on April 21, 2026, following Virginia voters' approval of a temporary redistricting measure. The approved measure was designed to push back against claims of entitlement to additional Republican seats in Congress. The statement acknowledges voter rejection of similar demands in other states and reaffirms commitment to Virginia's bipartisan redistricting commission resuming work after the 2030 census.

Additional Practical Exam Testing Date April 29, Montgomery

PSI, the Alabama Board of Cosmetology and Barbering testing partner, has added an additional practical exam testing date on April 29 in Montgomery, Alabama. This supplementary testing event precedes the launch of updated cosmetology and barbering examinations scheduled for May 1, 2026. Test takers are instructed to log into their PSI online portal, select Montgomery Practical as the site location, and schedule their exam before all available spots are filled.

Parole Hearing Outcomes Week of April 13-17, 2026

The California Board of Parole Hearings published outcomes for approximately 90 parole suitability hearings conducted during the week of April 13 through April 17, 2026, spanning multiple counties including Los Angeles, Riverside, San Bernardino, and others. Outcomes include Waive (1-3 year), Deny (3-5 year), Grant (under PC 3041.1 or PC 3041.2), Postpone (0-6 month), Stipulate (3 year), and one Rescission. These records reflect individual parole hearing determinations and do not create new compliance obligations for the public.

Health and Wellness Coaching for Thyroid Cancer Survivors, NCT07545837

Clinical trial NCT07545837 registered on ClinicalTrials.gov evaluates a patient-centered health and wellness coaching (HWC) intervention targeting adherence to treatment plans and healthy lifestyle practices in patients with papillary or follicular thyroid cancer. The trial will enroll thyroid cancer survivors who have undergone surgery, radioactive iodine, and/or lifelong levothyroxine therapy with regular thyroid stimulating hormone monitoring. Interventions include counseling, interviews, and questionnaire administration to assess HWC's impact on self-care, health-related goal-setting, and survivorship care outcomes.

Phase 1 CAR T Cell Trial for Recurrent High-Grade Gliomas

This Phase 1 clinical trial registered on ClinicalTrials.gov (NCT07544992) will evaluate the safety and optimal dosing of EGFR/IL13Rα2 pool-CAR T cells administered locoregionally (via intracranial catheter) in patients with recurrent or progressive high-grade gliomas, including recurrent astrocytoma (IDH-mutant, grade 4) and recurrent glioblastoma (IDH-wildtype). The trial involves leukapheresis to collect patient T cells, genetic engineering to express chimeric antigen receptors targeting EGFR and IL13Rα2 proteins on tumor cells, and subsequent infusion of the modified cells.

Effects of Exogenous Ketones on Cognitive Function in Older Adults With Prediabetes

This clinical trial registration (NCT07546409) describes a randomized study assessing whether older adults with prediabetes show differences in brain glucose uptake and cognitive processing speed compared to age-matched controls with normal glucose levels. The trial will test a single dose of an exogenous ketone monoester supplement (DeltaG) against placebo in approximately 100 participants, measuring outcomes via 18F-FDG-PET/MRI brain imaging and cognitive testing. Estimated study completion date is April 22, 2026.

Ultrasound-guided Pharmacopuncture Spinal Disease Registry Trial, 600 Patients, 6 Sites

The NIH ClinicalTrials.gov registry has posted an observational multi-center registry study (NCT07543692) evaluating the safety and effectiveness of ultrasound-guided pharmacopuncture for patients with spinal diseases. The study will enroll 600 patients aged 19 to under 70 across six Korean medicine hospitals, requiring a pain Numeric Rating Scale score of 5 or higher for eligibility. Participants already planned to receive ultrasound-guided pharmacopuncture as part of routine clinical care will be observed; the primary outcome is change in most dominant spinal pain intensity from baseline to 4 weeks. Secondary outcomes include functional disability (NDI/ODI), quality of life (EQ-5D-5L), and patient satisfaction, with safety monitored via adverse event assessment at every visit. This is a non-interventional registry study with no new compliance obligations for external parties.

Subclinical Atherosclerosis in Juvenile Systemic Lupus Erythematosus

A new observational study (NCT07545408) registered on ClinicalTrials.gov will evaluate subclinical atherosclerosis in children and adolescents with juvenile systemic lupus erythematosus (SLE) by measuring carotid intima-media thickness (CIMT), and will assess associations with both traditional cardiovascular risk factors (dyslipidemia, hypertension, obesity) and non-traditional disease-related risk factors (disease activity, lupus nephritis, corticosteroid dose, disease duration). The study is listed as observational with an anticipated end date.

RAB001 Phase 1, Osteonecrosis, 16 Healthy Subjects

A Phase 1 clinical trial for RAB001 (LLP2A-Ale) has been registered on ClinicalTrials.gov (NCT07545018) examining safety, tolerability, and pharmacokinetics in 16 healthy subjects across two dose groups (400 μg/kg and 750 μg/kg) for the treatment of Osteonecrosis of the Femoral Head. The single-center, randomized, double-blind, placebo-controlled dose escalation study includes both single-dose and multiple-dose phases with injections administered once every 2 weeks.

Observational Study Biomarkers Osteoarthritis China

ClinicalTrials.gov registered an observational study (NCT07544823) titled 'Screening for Biomarkers of Osteoarthritis' conducted in China, posted April 22, 2026. The study intends to collect blood samples from osteoarthritis patients and suspected patients at a tertiary hospital orthopedic outpatient department, using diagnostic and differential diagnostic tests to verify candidate biomarkers. Researchers aim to screen biomarkers with favorable validity and reliability to support early prevention, early diagnosis, and individualized intervention for osteoarthritis.

Combined Ovarian Tissue and Oocyte Cryopreservation for Fertility

NIH ClinicalTrials.gov registered observational study NCT07546123 will compare combined ovarian tissue cryopreservation with oocyte cryopreservation against oocyte cryopreservation alone in oncological patients undergoing gonadotoxic treatments. The study will collect data from two groups of patients assigned based on their planned gonadotoxic therapy and available time before treatment initiation. The primary endpoints are the number of oocytes retrieved per ovarian stimulation cycle and the oocyte retrieval rate between the two groups.

Phase 1 ISAR InflEx Trial: Exercise Inflammation CVD

A new Phase 1 clinical trial called ISAR InflEx (Inflammation and Exercise) has been registered on ClinicalTrials.gov under identifier NCT07543666, with an estimated start date of April 22, 2026. The trial will investigate how three distinct exercise modalities—moderate-intensity, vigorous-intensity, and short-duration maximal exercise—affect systemic inflammation and immune function in sedentary adults with obesity, a population at elevated risk for cardiovascular disease. The study aims to characterize exercise as a potential anti-inflammatory intervention for CVD prevention, enrolling participants who meet specific inclusion criteria related to sedentary behavior and weight status.

XR Resilience Training RCT for 232 Hospital Nurses

A new ClinicalTrials.gov registry entry (NCT07544498) describes a pragmatic randomized controlled trial evaluating an extended reality (XR) based resilience training program for approximately 232 hospital nurses across several European countries. The trial compares eight immersive XR training sessions delivered via head-mounted display over ten weeks against a waitlist control, measuring perceived stress as the primary outcome.

Protego Biopharma Heteroaryl Diamide IRE1/XBP1S Activator Patent EP4347568A1

The European Patent Office published patent application EP4347568A1 on 15 April 2026, filed by Protego Biopharma, Inc. and The Scripps Research Institute, covering heteroaryl diamide compounds as IRE1/XBP1S pathway activators. The application lists eight named inventors and spans multiple therapeutic classifications including metabolic, cardiovascular, musculoskeletal, and neurological disease indications. The patent is now publicly available and designates all EPC contracting states across the EU and beyond.

Macrocyclic Compounds for Treating Cancer (EP4151641A1)

European Patent Office published EP4151641A1 on April 15, 2026, covering macrocyclic compounds for treating cancer. The patent lists Turning Point Therapeutics, Inc. as applicant and eight named inventors, with IPC classifications spanning C07D 498/22, A61P 35/00, and A61K 31/5383. The patent designates all EU member states as covered jurisdictions, conferring exclusivity across the European market.

Novel Bridged Bicycloalkyl-Substituted Aminothiazoles and Their Methods of Use

Temple University of the Commonwealth System of Higher Education has been granted European Patent EP4219486A1 for novel bridged bicycloalkyl-substituted aminothiazole compounds and their methods of use, published April 15, 2026. The patent designates 31 European Patent Convention member states including Germany, France, the United Kingdom, Italy, Spain, and the Netherlands. Inventors include CHILDERS Wayne E., ABOU-GHARBIA Magid A., MORTON George C., ISSA Jean-Pierre J., and ZHANG Hanghang, with applications classified under A61K 31/426 (antineoplastic pharmaceutical preparations).

EPO Publishes MOF Linkers Patent Application by Universiteit Antwerpen

The EPO published patent application EP4326436A1 for MOF (Metal-Organic Framework) and MOF linkers and their manufacturing method, filed by Universiteit Antwerpen. The inventors are Christophe Vande Velde, Rosa Fucci, and Leili Esrafili-Dizaji. The application covers IPC classifications B01J 31/26 and C07D 333/40, relating to catalysts and heterocyclic compounds. The patent designates all standard European contracting states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Kumquat Biosciences EP4203952A1 Heterocyclic Compounds Patent

Kumquat Biosciences Inc. has obtained European patent publication EP4203952A1 for heterocyclic compounds and uses thereof, covering compositions with potential therapeutic applications. The patent names five inventors — Liu Yi, Ren Pingda, Li Liansheng, Zhu Zhimin, and Zhu Xiuwen — and was published on April 15, 2026. The application is designated across 31 European states including Germany, France, the United Kingdom, Italy, Spain, and the Netherlands, among others.

EP4122537A1 - Bridged Tricyclic Carbamoylpyridone Compounds

Gilead Sciences, Inc. has received EPO Publication EP4122537A1 for bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use, published on 15 April 2026. The application covers heterocyclic compounds with potential therapeutic applications, classified under IPC codes including C07D 471/04, C07D 491/06, and A61K 31/4375. The designation extends to 34 European states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Triazine Compound Salt Crystal Form, Tanabe Pharma, EP4215244A1, Apr 15 2026

The European Patent Office published patent EP4215244A1 on April 15, 2026, covering triazine compound salt crystal forms and production methods. The patent is assigned to Tanabe Pharma Corporation with four named inventors: Yamagami, Setsuta, Sugiura, and Ueda. The patent is designated across 31 European states including DE, FR, GB, IT, NL, ES, and SE.

IRBM Azole SHP2 Inhibitors Patent EP4345101A1

The European Patent Office published patent application EP4345101A1, filed by IRBM S.P.A. and C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening, covering azole derivatives as SHP2 inhibitors for therapeutic use. The application includes claims for treating cancer, immune disorders, and respiratory conditions, with inventors including Alessia Petrochchi, Christian Montalbetti, Romano Di Fabio, Alina Ciammaichella, and Ilaria Rossetti. The publication is designated for all European member states.

Captor Therapeutics European Patent Application EP4347579A1 for MCL-1 Targeted Protein Degradation

Captor Therapeutics S.A. has obtained publication of European patent application EP4347579A1 covering bifunctional compounds designed to bind ubiquitin ligase and recruit the MCL-1 protein for degradation, with potential therapeutic application in oncology. The application was published on April 15, 2026 with claims spanning heterocyclic compound compositions under IPC classifications C07D 401/14, C07D 471/04, C07D 513/04, and related therapeutic uses under A61P 35/00 and A61K 31/4439. The designated states include all EPC contracting states (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR).

Roche EP4251614A1: N-Substituted Aniline Hepatitis B Treatment

The EPO has granted patent EP4251614A1 to F. Hoffmann-La Roche AG covering N-substituted 4-(5-phenyl-1,3,4-oxadiazol-2-yl)aniline compounds for the treatment and prophylaxis of hepatitis B virus infection. The patent, filed with four named inventors (LIN Xianfeng, YUN Hongying, ZHANG Bo, ZHENG Xiufang), carries IPC classifications spanning C07D chemical compounds and A61K/A61P pharmaceutical preparations. Designated states include all major European Patent Convention member states. This grant confers exclusive rights to Roche across EU member jurisdictions for the claimed HBV therapeutic applications.

EP4144736A1 - Azabenzimidazoles AMPA Receptor Modulators, Janssen, Apr 15, 2026

The EPO published patent application EP4144736A1 titled 'Azabenzimidazoles and Their Use as AMPA Receptor Modulators' on April 15, 2026, covering novel heterocyclic compounds as AMPA receptor modulators for neurological and pain conditions. The application was filed by Janssen Pharmaceutica NV with 13 named inventors. The patent designates 37 EPO contracting states.

Celgene/Zoetis Helminthic Drug Patent Published by EPO

The European Patent Office published patent application EP4232449A1 for Celgene Corporation and Zoetis LLC, covering heterocyclic compounds and their use for treating helminthic infections and diseases, published April 15, 2026. The compounds carry multiple IPC classifications including C07D 417/14, C07D 413/14, C07D 401/14, C07D 471/04, C07D 491/048, and are designated across 31 European states including DE, FR, GB, IT, NL, ES, PL, SE. The publication establishes priority rights and enables public inspection of the specific heterocyclic compound compositions and therapeutic uses disclosed in the application.

ISO 14001 Updated to Drive Environmental Action

ISO has published ISO 14001:2026, an updated environmental management standard that shifts organizational focus from environmental reporting to active, risk-driven environmental management. The standard requires organizations to identify their most significant environmental aspects and concentrate resources where impacts and risks are greatest, rather than pursuing uniform actions. The new edition also strengthens alignment with other management system standards including ISO 9001 (quality), ISO 45001 (occupational health and safety), and ISO 50001 (energy management), allowing integrated implementation. Compliance and environmental management professionals should note that ISO 14001 is explicitly described as a governance framework supporting leadership in understanding environmental risk and aligning environmental performance with broader organizational objectives. The standard is positioned as applicable across diverse contexts from complex industrial sectors (oil and gas, chemical manufacturing, nuclear energy) to community organizations, emphasizing its flexibility in addressing varied organizational footprints.

UNDRR Chief: Critical Infrastructure Must Prioritize Resilience

The UNDRR Special Representative for Disaster Risk Reduction, Kamal Kishore, has published a thought leadership piece on ISO's website arguing that critical infrastructure resilience can no longer be optional. The article cites the Global Assessment Report on Disaster Risk Reduction 2025, noting that while direct disaster costs reach approximately USD 202 billion annually, the true cost is eleven times higher — nearly USD 2.3 trillion annually — when cascading and indirect impacts are included. The piece highlights ISO 22372, an international standard developed from the Principles for Resilient Infrastructure, as a practical pathway for achieving resilience and complements regulatory frameworks such as the EU's Resilience of Critical Entities (CER) Directive. Organizations responsible for critical infrastructure systems in energy, water, transport, and healthcare sectors should consider the standard as a benchmark for identifying hidden vulnerabilities and strengthening continuity of essential services under stress.

ISO 14001:2026 Published, Raising Environmental Performance Bar

ISO has published ISO 14001:2026, a revised edition of the world's most widely used environmental management standard, trusted by more than 670,000 certified organizations worldwide. The new edition introduces clearer guidance, stronger alignment with environmental priorities including climate change, biodiversity, and resource efficiency, and greater emphasis on leadership, governance, and integrated value-chain management. Organizations currently certified to ISO 14001 should monitor transition timelines from their certification bodies, while those not currently certified can consider adopting the revised standard.

Senate Rejects Iran War Powers Resolution 46-51

The Senate voted 46-51 on April 22, 2026 to reject the Motion to Discharge S.J.Res. 114, a joint resolution that would have directed the removal of United States Armed Forces from hostilities within or against Iran that have not been authorized by Congress. The measure required a simple majority to advance but fell short by five votes, with 51 senators voting no and three not voting. The resolution remains in committee and was not advanced to the full Senate for consideration.

Maldives Monthly Statistics March 2026 Economic Indicators

The Maldives Monetary Authority published Volume 27 Issue 3 of its Monthly Statistics for March 2026, covering economic, fiscal, monetary, and external sector data as available through 30 March 2026. The release includes tables on GDP, tourism indicators, fisheries production, inflation, government finance, financial soundness indicators, balance of payments, external trade, and exchange rates spanning 2020–2026. Data sources cited include the Maldives Bureau of Statistics, Ministry of Finance and Planning, Ministry of Tourism and Environment, Maldives Customs Service, and Maldives Monetary Authority.

Maldives GDP Grows 8.6% in Q3 2025, Tourist Arrivals Up 16%

According to advance estimates from the Maldives Bureau of Statistics, real GDP grew by 8.6% in Q3-2025 compared to the same quarter in 2024, driven primarily by expansion in tourism and fisheries. Tourism arrivals in February 2026 stood at 247,722, an increase of 16% year-on-year, with guesthouse bednights rising 42%. Annual GDP growth for 2025 is projected at 5.4%, revised downwards from prior forecasts, following estimated growth of 3.5% in 2024.

Maldives Monetary Authority Balance Sheet March 2026

The Maldives Monetary Authority published its Statement of Financial Position as of March 31, 2026. The balance sheet presents the central bank's assets and liabilities, including foreign currency balances of 17,072,572,510 MVR, investments in government securities, currency in circulation of 5,020,931,929 MVR, and total equity including capital of 50,000,000 MVR and reserves of 1,645,639,424 MVR. This is a routine monthly financial reporting document with no regulatory compliance obligations.

Commissioner Causey Recognizes 700 SHIIP Volunteers During National Volunteer Week

Insurance Commissioner Mike Causey recognized North Carolina's 700 SHIIP (Seniors' Health Insurance Information Program) certified counselors during National Volunteer Week 2026 (April 19–25). The program, preparing to celebrate 40 years of service in September 2026, has grown to cover all 100 counties serving North Carolina's 2.2 million Medicare beneficiaries. SHIIP volunteers counsel Medicare beneficiaries and caregivers about Medicare, Medicare supplements, Medicare Advantage, Medicare Part D, and long-term care insurance, with the NC Senior Medicare Patrol additionally helping seniors identify and report billing errors, fraud, abuse, and waste.

Commissioner Causey Negotiates 5% Annual Dwelling Rate Increase Over Two Years, Saving NC Consumers $268M

North Carolina Insurance Commissioner Mike Causey has settled a dwelling rate case with insurance companies, reducing the N.C. Rate Bureau's requested 68.3% two-year increase to an average statewide increase of 5% per year over the next two years. The negotiated settlement, effective October 1, 2026 and October 1, 2027, includes mitigation credits for consumers investing in fortified homes and roofs. A hearing on the proposed increase originally scheduled for July 6 has been canceled as a result of the settlement. Commissioner Causey stated the settlement saves North Carolina consumers more than $268 million compared to the insurance companies' original request.

EDPB 2025 Annual Report Stakeholder Guidance Focus

The European Data Protection Board published its 2025 Annual Report on 9 April 2026, covering the Helsinki Statement on enhanced clarity and stakeholder engagement, joint guidelines with the European Commission on the interplay between the Digital Markets Act and GDPR, and guidelines on the Digital Services Act and GDPR. The report also covers practical guidance on AI, pseudonymisation, and blockchain technologies.

EDPB Adopts Scientific Research Data Processing Guidelines

The EDPB adopted Guidelines on processing personal data for scientific research purposes, providing six indicative factors to determine if processing qualifies as scientific research under GDPR, and clarifying purpose compatibility, broad consent, and limitations on data subject rights. The Board also created a dedicated sprint team to accelerate finalisation of the upcoming anonymisation guidelines by summer. Two Europrivacy certification opinions were also adopted, including the first European Data Protection Seal approved as a transfer tool under Articles 42 and 46 GDPR. The scientific research guidelines are open for public consultation until 25 June 2026.

DOJ and FTC Extend Deadline for Collaborations Guidelines Comments

The Department of Justice and the Federal Trade Commission jointly announced an extension of the public comment period for the Antitrust Agencies' Draft Guidelines for Business Collaborations. The extension provides additional time for stakeholders to submit feedback on the draft guidelines, which outline the agencies' analytical framework for evaluating whether business collaborations may raise antitrust concerns under federal competition law.

Legal Decisions, Notices, Resources, Seminars for Workers' Compensation

The New Jersey Division of Workers' Compensation has published an updated legal information page aggregating recent court notices, rule amendments, and seminar announcements. The 2025 May Day Seminar is scheduled for May 5th from 1PM to 4PM at each court vicinage, covering Public Employee Issues, Ethical Use of AI, and Temporary Disability matters, with 3.6 CLE credits available including 1.2 ethics credits. Registration closes May 2, 2025 with the Head Clerk at each vicinage. Historical entries document the Thomas P. Canzanella Twenty First Century Responders Protection Act reporting requirements and 2022 rule amendments to N.J.A.C. 12:235-3.11, 3.12, and new rule 3.19.

Nine Individuals, Three Organizations Receive 2026 NHTSA Public Service Awards

NHTSA Administrator Jonathan Morrison presented 2026 NHTSA Public Service Award plaques to nine individuals and three organizations at the Lifesavers National Conference on Roadway Safety in Baltimore. Awardees were recognized for traffic safety achievements including a 50% reduction in traffic fatalities in Fairfax County, VA, the passage of Virginia House Bill 2475 for stronger seat belt legislation, and implementation of evidentiary oral fluid drug testing in New York State.

CRTC 2026-73: Declines Canada Deaf Grassroots Movement VRS Policy Review Application

The CRTC declined the Canada Deaf Grassroots Movement's application to review and vary Telecom Regulatory Policy 2025-54 on video relay service (VRS). The Commission found that CDGM did not establish substantial doubt as to the correctness of the updated VRS policy under section 62 of the Telecommunications Act. The decision preserves the current VRS policy, which enhanced inclusivity, usability, and flexibility for the Canadian Administrator of VRS (CAV), Inc.

TV5/UNIS TV Wholesale Rate Increase Approved by CRTC

The CRTC has approved TV5 Québec Canada's application to increase mandatory per subscriber monthly wholesale rates for TV5/UNIS TV by $0.02 across both market types: from $0.24 to $0.26 in English-language markets and from $0.28 to $0.30 in French-language markets. The decision, citing TV5's critical deteriorating financial situation that threatened its ability to fulfill programming obligations, modifies the existing mandatory distribution order issued under paragraph 9.1(1)(h) of the Broadcasting Act. The new rates take effect immediately upon publication of this decision (22 April 2026), and the modified distribution order will expire 31 August 2026.

CRTC Denies VRS Policy Review Request by Deaf and Hard of Hearing Coalition

The CRTC has denied an application by the Deaf and Hard of Hearing Coalition (DHH Coalition) to review and vary Telecom Regulatory Policy 2025-54, which updated Canada's Video Relay Service (VRS) policy. The Commission found that the applicant failed to establish substantial doubt as to the correctness of the updated VRS policy, which had made the service more inclusive, enhanced its usability, and given the Canadian Administrator of VRS (CAV) flexibility to evolve with technological advances. The DHH Coalition had argued that maintaining minimum requirements and a funding cap on CAV limits VRS development and prevents parity with telephone service available to hearing persons.

ICE Houston Arrests 277 Criminal Aliens in 2 Weeks Including Child Predators, Murderers

ICE Houston announced the arrests of 277 criminal aliens between April 6 and April 17, 2026, who were collectively convicted of 751 criminal offenses and had illegally entered the United States 654 times. Among those arrested were 17 child predators, 6 murderers, 16 drug traffickers, 15 gang members or associates, 67 robbers, 2 foreign fugitives wanted for murder, and 11 aliens convicted of hit-and-run. The operation was conducted with assistance from federal, state, and local law enforcement partners.

14 Final Ethics Adjudications, $250-$750 Penalties for Late SFI Filings

The Pennsylvania State Ethics Commission issued 14 final adjudications on April 21, 2026, imposing civil penalties on public officials for failing to file required Statements of Financial Interests under Section 1104(a) of the Public Official and Employee Ethics Act, 65 Pa.C.S. § 1104(a). Penalties ranged from $150 (single-year delinquency) to $750 (three-year delinquency), calculated at $25 per day of delinquency. All respondents were ordered to pay within 30 days and to file missing Statements. Failure to comply triggers additional enforcement action.

OFAC Expands Venezuela Sanctions Relief with New General Licenses 56 and 57

On April 14, 2026, OFAC issued General License 56, authorizing U.S. persons to conduct commercial-related negotiations of contingent contracts with the Government of Venezuela, and General License 57, authorizing financial services transactions involving four named Venezuelan banks and individuals blocked solely under E.O. 13884. GL 57 defines 'financial services' broadly and allows processing institutions to rely on originator or beneficiary representations regarding GL 57 compliance. For commercial sector participants, GL 56 removes the need for an individual license at the negotiation stage, while GL 57 gives U.S. and foreign financial institutions a clearer legal basis to support the expanding scope of authorized Venezuela dealings.

Annual Report NSP 2025 Available PDF

The Bank of Slovenia (BoS) has published the Annual Report NSP 2025, making it available in PDF format on its website. This is a routine annual publication from the Slovenian banking supervisor documenting national strategic plan activities. Users requiring access should follow the link provided on the BoS publications page to retrieve the full report.

Slovenia Q1 Growth 0.4%, Inflation 2.4%, Risks Rise

The Bank of Slovenia's April 2026 macroeconomic review reports domestic economic activity growth of 0.4% quarter-on-quarter in Q1, with headline HICP inflation slowing to 2.4% in March and core inflation unchanged at 2.3%. The review identifies heightened risks stemming from the Middle East conflict, including increased cost pressures, supply chain disruptions, deteriorating consumer confidence, and fiscal deficit widening to 2.5% of GDP, while wage growth accelerated sharply at 16% due to minimum wage increases and trade contracted in both exports and imports.

Slovenia Q1 Growth Continues, War Inflation Rises, Consumption Slows

Banka Slovenije published its April 2026 macroeconomic review, reporting that Slovenia's economy continued to grow in Q1 2026, though domestic consumption slowed and industrial production remained weak. Headline inflation eased to 2.4% in March, while the minimum wage rose 16% — the second-largest increase in two decades and the largest in the EU this year. The direct impact of the war in the Middle East is being reflected in a sharp rise in consumers' inflation expectations, with broader economic risks to growth and the fiscal outlook expected to strengthen over the remainder of 2026.